At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 130 enrolled
Drug / intervention
GSK investigational vaccine GSK2340272A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years
In Brief
A Phase 3 clinical trial evaluating GSK investigational vaccine GSK2340272A and GSK investigational vaccine GSK2340269A for Influenza. Completed, enrolled 130 participants across 1 site.
Detailed Summary
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesBelgium
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionSep 2010
TodayJul 2026
First PostedAug 31, 2009
Enrollment StartSep 8, 2009
Primary CompletionSep 28, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.8 years ago
Interventions
GSK investigational vaccine GSK2340272Abiological
Two intramuscular injections
GSK investigational vaccine GSK2340269Abiological
Two intramuscular injections